<DOC>
	<DOCNO>NCT02962063</DOCNO>
	<brief_summary>The purpose study test safety add new drug , durvalumab ( also call MEDI4736 ) , chemoradiation use two standard chemotherapy drug , carboplatin paclitaxel . The investigator want find effect , good and/or bad , combination patient cancer .</brief_summary>
	<brief_title>Durvalumab , Anti-PD-L1 Antibody , Chemoradiation Before Surgery Esophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma esophagus gastroesophageal junction ( GEJ ) . Pathology must confirm Memorial Sloan Kettering Cancer Center Tumors Her2 positive eligible Availability archive tumor tissue banking TanyN+M0 T34NanyM0 tumor Disease must clinically limited esophagus GEJ . GEJ tumor must Siewert Type IIII No prior chemotherapy Prior radiation permit , provide limit ability deliver perprotocol radiation opinion treat radiation oncologist Patients must surgically resectable disease treatable esophagectomy , assess thoracic surgeon Patients must ≥18 year age Eastern Cooperative Oncology Group performance status 01 Female subject must either nonreproductive potential ( i.e . postmenopausal history : ≥60 year old menses ≥1 year without alternative medical cause ; OR history hysterectomy , OR history bilateral tubal ligation , OR history bilateral oophorectomy ) must negative serum pregnancy test upon study entry Adequate organ function define baseline : WBC ≥3,000/ L ANC ≥1,500/ L Platelets ≥100,000/ L Hb ≥9 g/dl Calculated creatinine clearance &gt; 40 ml/min use CockcroftGault method : Males : Creatinine CL = Weight ( kg ) x ( 140 Age ) . ( mL/min ) 72 x serum creatinine ( mg/dL ) Females : Creatinine CL ( mL/min ) = Weight ( kg ) x ( 140 Age ) x 0.85 72 x serum creatinine ( mg/dL ) Total serum bilirubin ≤1.5 mg/dL AST/ALT ≤2.5× upper limit normal Mean QT interval correct heart rate ( QTc ) &lt; 470 m calculate 3 ECGs use Frediricia 's Correction Able provide write informed consent Subject willing provide inform consent MSKCC IRB # 12245 IMPACT test Subject willing able comply protocol duration study include undergoing treatment schedule visit examination include follow Carcinoma insitu tumor determine T12N0 Tumors significant involvement proximal stomach , opinion treat thoracic surgeon , would require esophagogastrectomy Patients evidence metastatic disease , include : Positive malignant cytology pleural , pericardium peritoneum Radiographic evidence distant organ involvement Nonregional lymph node contain within radiation field Biopsyproven tumor invasion tracheobronchial tree presence tracheoesophageal fistula . Recurrent laryngeal phrenic nerve paralysis Active prior document autoimmune inflammatory disorder ( include inflammatory bowel disease ; systemic lupus erythematosus ; Wegener syndrome [ granulomatosis polyangiitis ] ; myasthenia gravis ; Graves ' disease ; rheumatoid arthritis , hypophysitis , uveitis ) within past 3 year prior start treatment . The following exception criterion : Subjects vitiligo alopecia Subjects hypothyroidism ( e.g. , follow Hashimoto syndrome ) stable hormone replacement psoriasis require systemic treatment History pneumonitis The use immunosuppressive medication within 28 day prior first dose durvalumab . The following exception criterion : Intranasal , topical , inhaled corticosteroid local steroid injection ( e.g . intraarticular injection ) Systemic corticosteroid physiologic dos ≤10 mg/day prednisone equivalent Steroids premedication hypersensitivity reaction ( e.g . CT scan premedication ) Known HIV positivity Chronic Hepatitis B C infection ( e.g . Hepatitis B surface Ag positive detectable viral load Hepatitis B C ) . Patients prior evidence Hepatitis B C without active infection eligible Known history previous clinical diagnosis tuberculosis Uncontrolled seizure Pregnant breastfeed woman . Women childbearing potential ( WOCBP ) must undergo negative pregnancy test ( either serum urine ) prior study entry . Male female patient reproductive potential need employ two highly effective acceptable form contraception throughout participation study 90 day last dose study drug . WOCBP include : Any woman experience menarche undergone surgical sterilization ( hysterectomy , bilateral tubal ligation oophorectomy ) postmenopausal ( define amenorrheic ≥12 consecutive month ) Women hormone replacement therapy document serum follicle stimulate hormone level &gt; 35 mIU/ml Women use oral , implanted injectable contraceptive hormone mechanical product intrauterine device barrier method prevent pregnancy practice abstinence partner sterile Prior malignancy ( basal cell/squamous cell carcinoma skin , insitu cervical carcinoma superficial transitional cell bladder carcinoma ) diagnose and/or treat within three year study entry Connective tissue disorder , e.g . scleroderma , opinion treat physician contraindication radiation therapy History primary immunodeficiency History allogenic organ transplant Receipt live attenuate vaccination within 30 day prior study entry within 30 day receive durvalumab . For example , intramuscular influenza vaccine administer intranasal vaccine live attenuate virus give Any previous treatment PD1 PDL1 inhibitor , include durvalumab History hypersensitivity durvalumab excipient Uncontrolled intercurrent illness include limited , ongoing active infection , symptomatic congestive heart failure , uncontrolled hypertension , unstable angina pectoris , cardiac arrhythmia , active peptic ulcer disease , active bleeding diatheses psychiatric illness/social situation would limit compliance study requirement compromise ability subject give write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Durvalumab</keyword>
	<keyword>Anti-PD-L1 Antibody</keyword>
	<keyword>16-1405</keyword>
</DOC>